Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunoassay | 12 | 2024 | 92 | 2.840 |
Why?
|
Pharmacogenetics | 12 | 2023 | 434 | 2.000 |
Why?
|
Clinical Chemistry Tests | 4 | 2019 | 11 | 1.830 |
Why?
|
Antibodies, Viral | 4 | 2022 | 293 | 1.760 |
Why?
|
Tandem Mass Spectrometry | 4 | 2024 | 103 | 1.290 |
Why?
|
Tacrolimus | 2 | 2024 | 373 | 1.280 |
Why?
|
Precision Medicine | 5 | 2023 | 395 | 1.220 |
Why?
|
Immunoglobulin M | 4 | 2021 | 154 | 1.200 |
Why?
|
Pre-Eclampsia | 5 | 2022 | 246 | 1.060 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 4 | 2022 | 91 | 0.980 |
Why?
|
Automation, Laboratory | 2 | 2020 | 10 | 0.940 |
Why?
|
Peptide Fragments | 6 | 2011 | 460 | 0.920 |
Why?
|
Placenta Growth Factor | 4 | 2022 | 70 | 0.870 |
Why?
|
Natriuretic Peptide, Brain | 5 | 2011 | 56 | 0.860 |
Why?
|
Drug Monitoring | 2 | 2024 | 118 | 0.840 |
Why?
|
Thyroid Function Tests | 1 | 2022 | 119 | 0.830 |
Why?
|
Spike Glycoprotein, Coronavirus | 1 | 2022 | 40 | 0.830 |
Why?
|
Biomarkers | 10 | 2023 | 1718 | 0.800 |
Why?
|
Communicable Diseases, Imported | 1 | 2021 | 1 | 0.800 |
Why?
|
Serologic Tests | 1 | 2020 | 41 | 0.760 |
Why?
|
Blood Specimen Collection | 2 | 2012 | 27 | 0.760 |
Why?
|
Betacoronavirus | 2 | 2020 | 258 | 0.760 |
Why?
|
Triiodothyronine | 1 | 2022 | 339 | 0.740 |
Why?
|
Hyperkalemia | 2 | 2012 | 43 | 0.730 |
Why?
|
Humans | 75 | 2024 | 86617 | 0.700 |
Why?
|
Endothelial Growth Factors | 10 | 1996 | 55 | 0.700 |
Why?
|
Lymphokines | 10 | 1996 | 76 | 0.700 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2019 | 41 | 0.660 |
Why?
|
Parathyroidectomy | 1 | 2019 | 78 | 0.650 |
Why?
|
Vitamin B 12 | 1 | 2018 | 24 | 0.650 |
Why?
|
Smith-Lemli-Opitz Syndrome | 1 | 2018 | 2 | 0.650 |
Why?
|
Parathyroid Hormone | 1 | 2019 | 218 | 0.620 |
Why?
|
Adalimumab | 1 | 2018 | 80 | 0.620 |
Why?
|
Testosterone | 2 | 2017 | 271 | 0.600 |
Why?
|
Hypogonadism | 1 | 2017 | 37 | 0.600 |
Why?
|
Pharmacogenomic Testing | 4 | 2022 | 97 | 0.580 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 3 | 2011 | 44 | 0.570 |
Why?
|
Proteomics | 1 | 2018 | 212 | 0.570 |
Why?
|
Developmental Disabilities | 1 | 2018 | 195 | 0.560 |
Why?
|
Chromatography, Liquid | 3 | 2024 | 104 | 0.560 |
Why?
|
Cytochrome P-450 CYP2D6 | 5 | 2022 | 52 | 0.550 |
Why?
|
Immunoglobulin G | 4 | 2021 | 456 | 0.550 |
Why?
|
Cholesterol | 1 | 2018 | 356 | 0.550 |
Why?
|
Chorionic Gonadotropin | 2 | 2014 | 72 | 0.540 |
Why?
|
Sensitivity and Specificity | 6 | 2022 | 1991 | 0.530 |
Why?
|
Fibromyalgia | 1 | 2015 | 14 | 0.530 |
Why?
|
Hemolysis | 3 | 2023 | 61 | 0.520 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2014 | 39 | 0.500 |
Why?
|
Immunosuppressive Agents | 2 | 2024 | 977 | 0.490 |
Why?
|
Analgesics | 1 | 2015 | 119 | 0.490 |
Why?
|
Genotype | 7 | 2022 | 1851 | 0.470 |
Why?
|
Myocardial Ischemia | 2 | 2005 | 162 | 0.470 |
Why?
|
Carcinoma, Papillary | 1 | 2014 | 158 | 0.450 |
Why?
|
Chronic Pain | 1 | 2015 | 145 | 0.440 |
Why?
|
Reagent Kits, Diagnostic | 4 | 2020 | 39 | 0.440 |
Why?
|
Reproducibility of Results | 7 | 2021 | 2705 | 0.430 |
Why?
|
Troponin I | 3 | 2003 | 27 | 0.410 |
Why?
|
Nerve Tissue Proteins | 2 | 2004 | 503 | 0.390 |
Why?
|
Diagnostic Errors | 1 | 2012 | 160 | 0.390 |
Why?
|
Potassium | 1 | 2012 | 281 | 0.390 |
Why?
|
Genotyping Techniques | 1 | 2011 | 68 | 0.380 |
Why?
|
Legislation, Medical | 1 | 2010 | 9 | 0.380 |
Why?
|
Artifacts | 1 | 2012 | 244 | 0.370 |
Why?
|
Warfarin | 2 | 2019 | 103 | 0.370 |
Why?
|
Thyroid Neoplasms | 1 | 2014 | 408 | 0.360 |
Why?
|
Anticoagulants | 3 | 2019 | 408 | 0.360 |
Why?
|
Antibodies, Heterophile | 2 | 2000 | 20 | 0.360 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2021 | 2357 | 0.350 |
Why?
|
Oxycodone | 2 | 2022 | 35 | 0.320 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2014 | 1313 | 0.320 |
Why?
|
False Positive Reactions | 4 | 2020 | 216 | 0.310 |
Why?
|
Female | 23 | 2022 | 44509 | 0.300 |
Why?
|
Pregnancy | 7 | 2022 | 2894 | 0.300 |
Why?
|
Limit of Detection | 2 | 2018 | 20 | 0.280 |
Why?
|
Rifampin | 1 | 2006 | 22 | 0.280 |
Why?
|
Protein Precursors | 2 | 2011 | 143 | 0.270 |
Why?
|
Exercise | 2 | 2005 | 315 | 0.260 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 199 | 0.260 |
Why?
|
Tissue Inhibitor of Metalloproteinase-2 | 1 | 2023 | 24 | 0.230 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2023 | 68 | 0.230 |
Why?
|
Predictive Value of Tests | 4 | 2018 | 1673 | 0.220 |
Why?
|
Cardiolipins | 1 | 2002 | 17 | 0.220 |
Why?
|
Erythrocyte Transfusion | 2 | 2013 | 60 | 0.220 |
Why?
|
Tramadol | 1 | 2022 | 14 | 0.210 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2005 | 318 | 0.210 |
Why?
|
Pain Management | 2 | 2021 | 127 | 0.210 |
Why?
|
Erythrocytes | 2 | 2013 | 255 | 0.210 |
Why?
|
Prostate-Specific Antigen | 1 | 2024 | 353 | 0.200 |
Why?
|
Perioperative Care | 2 | 2022 | 161 | 0.200 |
Why?
|
Travel Medicine | 1 | 2021 | 1 | 0.200 |
Why?
|
Adult | 18 | 2022 | 25640 | 0.200 |
Why?
|
Autoantibodies | 1 | 2002 | 267 | 0.200 |
Why?
|
Cross Reactions | 1 | 2021 | 106 | 0.200 |
Why?
|
Fetal Growth Retardation | 1 | 2021 | 66 | 0.190 |
Why?
|
Infant, Newborn | 4 | 2022 | 2378 | 0.190 |
Why?
|
Jaundice | 1 | 2020 | 14 | 0.190 |
Why?
|
Liver | 1 | 2006 | 1230 | 0.190 |
Why?
|
Blood Proteins | 1 | 2001 | 144 | 0.190 |
Why?
|
Equipment Design | 2 | 2021 | 406 | 0.190 |
Why?
|
Middle Aged | 14 | 2021 | 25017 | 0.190 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 73 | 0.190 |
Why?
|
Male | 17 | 2024 | 40958 | 0.190 |
Why?
|
Thyroid Gland | 1 | 2022 | 270 | 0.190 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2020 | 24 | 0.190 |
Why?
|
Genomics | 2 | 2019 | 720 | 0.190 |
Why?
|
Hepatitis B Antibodies | 1 | 2020 | 15 | 0.190 |
Why?
|
Indicators and Reagents | 1 | 2000 | 72 | 0.180 |
Why?
|
Hyperglycemia | 2 | 2001 | 176 | 0.180 |
Why?
|
Blood Chemical Analysis | 1 | 2000 | 42 | 0.180 |
Why?
|
Pharmacogenomic Variants | 1 | 2020 | 41 | 0.180 |
Why?
|
Platelet Function Tests | 1 | 2019 | 11 | 0.180 |
Why?
|
Hyperlipidemias | 1 | 2020 | 95 | 0.180 |
Why?
|
Mixed Function Oxygenases | 2 | 2010 | 68 | 0.180 |
Why?
|
Glycoproteins | 1 | 2001 | 234 | 0.180 |
Why?
|
Inpatients | 1 | 2022 | 297 | 0.180 |
Why?
|
Vascular Endothelial Growth Factors | 10 | 1996 | 56 | 0.180 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 295 | 0.170 |
Why?
|
Peripartum Period | 1 | 2019 | 20 | 0.170 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2019 | 30 | 0.170 |
Why?
|
Intraoperative Period | 1 | 2019 | 90 | 0.170 |
Why?
|
High-Throughput Screening Assays | 1 | 2019 | 55 | 0.170 |
Why?
|
Medication Adherence | 1 | 2020 | 129 | 0.170 |
Why?
|
Decision Support Techniques | 1 | 2020 | 160 | 0.170 |
Why?
|
Decision Support Systems, Clinical | 1 | 2019 | 103 | 0.160 |
Why?
|
Dehydrocholesterols | 1 | 2018 | 2 | 0.160 |
Why?
|
Serotonin | 1 | 2019 | 218 | 0.160 |
Why?
|
Biological Availability | 1 | 2018 | 92 | 0.160 |
Why?
|
Chromatography, High Pressure Liquid | 3 | 2019 | 315 | 0.160 |
Why?
|
Vascular Endothelial Growth Factor A | 10 | 1996 | 407 | 0.150 |
Why?
|
Anesthesiology | 1 | 2019 | 157 | 0.150 |
Why?
|
Prognosis | 4 | 2019 | 3675 | 0.150 |
Why?
|
Myocardium | 1 | 2000 | 529 | 0.150 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 413 | 0.150 |
Why?
|
Administration, Cutaneous | 2 | 2015 | 58 | 0.150 |
Why?
|
Vitamin D | 1 | 2019 | 261 | 0.150 |
Why?
|
Blood Pressure | 3 | 2019 | 1143 | 0.150 |
Why?
|
Pilot Projects | 2 | 2018 | 839 | 0.140 |
Why?
|
Ovarian Hyperstimulation Syndrome | 1 | 1996 | 5 | 0.140 |
Why?
|
Critical Care | 1 | 2019 | 370 | 0.140 |
Why?
|
Fluoroimmunoassay | 2 | 1994 | 2 | 0.140 |
Why?
|
Prospective Studies | 6 | 2023 | 4212 | 0.140 |
Why?
|
Diabetic Retinopathy | 2 | 1994 | 87 | 0.140 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 241 | 0.140 |
Why?
|
Libido | 1 | 2015 | 8 | 0.130 |
Why?
|
Myalgia | 1 | 2015 | 7 | 0.130 |
Why?
|
Heart Failure | 1 | 2005 | 1204 | 0.130 |
Why?
|
Case-Control Studies | 4 | 2020 | 1804 | 0.130 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2001 | 567 | 0.130 |
Why?
|
Health Promotion | 1 | 2017 | 160 | 0.130 |
Why?
|
Gels | 1 | 2015 | 48 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
Quality Control | 2 | 2012 | 117 | 0.130 |
Why?
|
Blood Glucose | 3 | 2017 | 873 | 0.120 |
Why?
|
Vitreous Body | 1 | 1994 | 54 | 0.120 |
Why?
|
Cytochrome P-450 CYP2C19 | 2 | 2011 | 7 | 0.120 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2018 | 683 | 0.120 |
Why?
|
Fatigue | 1 | 2015 | 174 | 0.120 |
Why?
|
Calibration | 1 | 2014 | 99 | 0.120 |
Why?
|
Mass Spectrometry | 2 | 2014 | 188 | 0.120 |
Why?
|
Time Factors | 5 | 2012 | 5209 | 0.120 |
Why?
|
Blood Preservation | 1 | 2013 | 10 | 0.120 |
Why?
|
Hemoglobin, Sickle | 1 | 2013 | 19 | 0.120 |
Why?
|
Hyperammonemia | 1 | 2013 | 10 | 0.120 |
Why?
|
Vitamin K Epoxide Reductases | 2 | 2010 | 16 | 0.110 |
Why?
|
Cytochrome P-450 CYP2C9 | 2 | 2010 | 21 | 0.110 |
Why?
|
Hypertension | 3 | 2018 | 1141 | 0.110 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 1565 | 0.110 |
Why?
|
Centrifugation | 1 | 2012 | 24 | 0.110 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2018 | 930 | 0.110 |
Why?
|
Phlebotomy | 1 | 2012 | 21 | 0.110 |
Why?
|
Prostatic Neoplasms | 1 | 2024 | 1721 | 0.110 |
Why?
|
Anemia, Sickle Cell | 1 | 2013 | 131 | 0.100 |
Why?
|
Chest Pain | 1 | 2011 | 42 | 0.100 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2001 | 1373 | 0.100 |
Why?
|
Ambulatory Care Facilities | 1 | 2012 | 102 | 0.100 |
Why?
|
Smoking | 2 | 2006 | 609 | 0.100 |
Why?
|
Acute Coronary Syndrome | 1 | 2011 | 45 | 0.100 |
Why?
|
Drug Industry | 1 | 2011 | 54 | 0.100 |
Why?
|
Alleles | 2 | 2011 | 1128 | 0.090 |
Why?
|
Drug Therapy | 1 | 2010 | 70 | 0.090 |
Why?
|
Insulin | 2 | 2006 | 1160 | 0.090 |
Why?
|
Genetic Markers | 1 | 2010 | 476 | 0.090 |
Why?
|
Cell Line | 2 | 2011 | 2468 | 0.090 |
Why?
|
Glucuronosyltransferase | 1 | 2010 | 184 | 0.090 |
Why?
|
Pain | 2 | 2022 | 391 | 0.090 |
Why?
|
Vancomycin | 1 | 1989 | 72 | 0.080 |
Why?
|
Pharmaceutical Preparations | 1 | 2010 | 92 | 0.080 |
Why?
|
United States Food and Drug Administration | 1 | 2009 | 127 | 0.080 |
Why?
|
Troponin T | 2 | 2011 | 37 | 0.080 |
Why?
|
Neoplasms | 2 | 2021 | 2898 | 0.080 |
Why?
|
Leukocyte Count | 1 | 2008 | 220 | 0.080 |
Why?
|
Emergency Service, Hospital | 1 | 2011 | 484 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 879 | 0.070 |
Why?
|
Surveys and Questionnaires | 1 | 2015 | 2501 | 0.070 |
Why?
|
Aged | 7 | 2021 | 18402 | 0.070 |
Why?
|
Nanotechnology | 1 | 2007 | 68 | 0.070 |
Why?
|
Sequence Deletion | 1 | 2007 | 205 | 0.070 |
Why?
|
Gene Duplication | 1 | 2007 | 125 | 0.070 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2006 | 40 | 0.070 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2006 | 43 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 1169 | 0.070 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2006 | 79 | 0.070 |
Why?
|
Narcotics | 1 | 2006 | 69 | 0.070 |
Why?
|
Hydrocortisone | 2 | 2004 | 298 | 0.070 |
Why?
|
Molecular Structure | 1 | 2006 | 287 | 0.070 |
Why?
|
Practice Patterns, Physicians' | 2 | 2021 | 581 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2005 | 159 | 0.060 |
Why?
|
Algorithms | 1 | 2013 | 1830 | 0.060 |
Why?
|
Cohort Studies | 3 | 2019 | 2767 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2007 | 689 | 0.060 |
Why?
|
Diabetes Mellitus | 2 | 2017 | 806 | 0.060 |
Why?
|
Radionuclide Imaging | 1 | 2004 | 220 | 0.060 |
Why?
|
Human Growth Hormone | 1 | 2004 | 54 | 0.060 |
Why?
|
Edetic Acid | 1 | 2003 | 43 | 0.060 |
Why?
|
Exercise Test | 1 | 2004 | 164 | 0.060 |
Why?
|
Regression Analysis | 1 | 2005 | 596 | 0.060 |
Why?
|
Risk Assessment | 2 | 2022 | 2261 | 0.060 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2023 | 22 | 0.060 |
Why?
|
Ischemia | 1 | 2005 | 243 | 0.060 |
Why?
|
Adolescent | 3 | 2021 | 8979 | 0.060 |
Why?
|
Hypoglycemic Agents | 1 | 2006 | 378 | 0.060 |
Why?
|
Aspartate Aminotransferases | 1 | 2023 | 73 | 0.060 |
Why?
|
Bilirubin | 1 | 2023 | 125 | 0.060 |
Why?
|
Pharmacists | 1 | 2022 | 32 | 0.060 |
Why?
|
United States | 2 | 2019 | 6665 | 0.050 |
Why?
|
Treatment Outcome | 1 | 2015 | 7990 | 0.050 |
Why?
|
Nicotine | 1 | 2004 | 194 | 0.050 |
Why?
|
Temperature | 1 | 2003 | 396 | 0.050 |
Why?
|
Omeprazole | 1 | 2022 | 11 | 0.050 |
Why?
|
Succinylcholine | 1 | 2022 | 14 | 0.050 |
Why?
|
Hydralazine | 1 | 2022 | 20 | 0.050 |
Why?
|
ROC Curve | 1 | 2004 | 752 | 0.050 |
Why?
|
Methylprednisolone | 1 | 2002 | 66 | 0.050 |
Why?
|
Young Adult | 3 | 2021 | 5974 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2021 | 6501 | 0.050 |
Why?
|
Dibenzothiazepines | 1 | 2001 | 4 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 376 | 0.050 |
Why?
|
Inflammation Mediators | 1 | 2002 | 154 | 0.050 |
Why?
|
Risperidone | 1 | 2001 | 23 | 0.050 |
Why?
|
Heart Diseases | 1 | 2003 | 290 | 0.050 |
Why?
|
Long QT Syndrome | 1 | 2001 | 34 | 0.050 |
Why?
|
Phenotype | 1 | 2007 | 2378 | 0.050 |
Why?
|
Coronary Artery Bypass | 1 | 2002 | 228 | 0.050 |
Why?
|
Antipsychotic Agents | 1 | 2001 | 123 | 0.050 |
Why?
|
Evaluation Studies as Topic | 1 | 2000 | 274 | 0.050 |
Why?
|
Early Detection of Cancer | 1 | 2024 | 392 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2002 | 352 | 0.040 |
Why?
|
Binding, Competitive | 1 | 2019 | 145 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2002 | 339 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2019 | 8477 | 0.040 |
Why?
|
Quality Improvement | 1 | 2023 | 428 | 0.040 |
Why?
|
Drug Prescriptions | 1 | 2020 | 141 | 0.040 |
Why?
|
Morbidity | 1 | 2019 | 148 | 0.040 |
Why?
|
Point-of-Care Systems | 1 | 2019 | 141 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 456 | 0.040 |
Why?
|
Aortic Aneurysm | 1 | 1998 | 80 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2020 | 257 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2021 | 1019 | 0.040 |
Why?
|
Pain, Postoperative | 1 | 2019 | 240 | 0.040 |
Why?
|
Pregnancy Outcome | 1 | 2018 | 247 | 0.040 |
Why?
|
Follicular Fluid | 1 | 1996 | 10 | 0.040 |
Why?
|
Ascitic Fluid | 1 | 1996 | 37 | 0.040 |
Why?
|
Ovulation Induction | 1 | 1996 | 33 | 0.030 |
Why?
|
Osmolar Concentration | 1 | 1996 | 181 | 0.030 |
Why?
|
Semen | 1 | 1995 | 13 | 0.030 |
Why?
|
Biomarkers, Tumor | 1 | 2024 | 1464 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2019 | 3636 | 0.030 |
Why?
|
Cardiopulmonary Bypass | 2 | 2002 | 148 | 0.030 |
Why?
|
Mitogens | 1 | 1995 | 64 | 0.030 |
Why?
|
Seminal Vesicles | 1 | 1995 | 39 | 0.030 |
Why?
|
Protein Binding | 1 | 2019 | 1456 | 0.030 |
Why?
|
Birth Weight | 1 | 1995 | 145 | 0.030 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 1995 | 18 | 0.030 |
Why?
|
Fetal Blood | 1 | 1995 | 90 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 864 | 0.030 |
Why?
|
DNA, Complementary | 1 | 1996 | 393 | 0.030 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 1995 | 104 | 0.030 |
Why?
|
Survival Rate | 1 | 2019 | 1860 | 0.030 |
Why?
|
Receptors, Growth Factor | 1 | 1994 | 52 | 0.030 |
Why?
|
Infant | 1 | 2021 | 3045 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 636 | 0.030 |
Why?
|
Cross-Over Studies | 2 | 2006 | 399 | 0.030 |
Why?
|
Pandemics | 1 | 2020 | 740 | 0.030 |
Why?
|
Chicago | 1 | 2018 | 1379 | 0.030 |
Why?
|
Leukocyte Reduction Procedures | 1 | 2013 | 3 | 0.030 |
Why?
|
Hematocrit | 1 | 2013 | 68 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 1996 | 353 | 0.030 |
Why?
|
Ammonia | 1 | 2013 | 37 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 1994 | 153 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2019 | 1801 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 1995 | 435 | 0.030 |
Why?
|
Automation | 1 | 2013 | 106 | 0.030 |
Why?
|
Fibrin | 1 | 1992 | 84 | 0.030 |
Why?
|
Microcirculation | 1 | 1992 | 106 | 0.030 |
Why?
|
Europium | 1 | 1992 | 2 | 0.030 |
Why?
|
Guinea Pigs | 1 | 1992 | 171 | 0.030 |
Why?
|
Prostate | 1 | 1995 | 378 | 0.030 |
Why?
|
Antibody Specificity | 1 | 1992 | 129 | 0.030 |
Why?
|
Body Weight | 1 | 2013 | 459 | 0.030 |
Why?
|
Animals | 3 | 2005 | 26582 | 0.030 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2011 | 26 | 0.030 |
Why?
|
Melanoma | 1 | 1996 | 454 | 0.030 |
Why?
|
Fatty Acids, Nonesterified | 1 | 2011 | 70 | 0.030 |
Why?
|
Greece | 1 | 2011 | 19 | 0.030 |
Why?
|
Psoriasis | 1 | 1994 | 240 | 0.020 |
Why?
|
Risk Factors | 2 | 2020 | 5417 | 0.020 |
Why?
|
Albumins | 1 | 2011 | 133 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 1994 | 3030 | 0.020 |
Why?
|
Pathology, Molecular | 1 | 2010 | 34 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 1995 | 1621 | 0.020 |
Why?
|
Obesity | 1 | 2017 | 963 | 0.020 |
Why?
|
Autoanalysis | 1 | 1989 | 6 | 0.020 |
Why?
|
Atrial Natriuretic Factor | 1 | 1989 | 39 | 0.020 |
Why?
|
Heart Arrest, Induced | 1 | 1989 | 31 | 0.020 |
Why?
|
Creatine | 1 | 1989 | 23 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 1989 | 303 | 0.020 |
Why?
|
Hypothermia, Induced | 1 | 1989 | 74 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2004 | 1823 | 0.020 |
Why?
|
Digoxin | 1 | 1987 | 21 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 1992 | 2062 | 0.020 |
Why?
|
Absorption | 1 | 2006 | 25 | 0.020 |
Why?
|
Glucose Clamp Technique | 1 | 2006 | 39 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2006 | 117 | 0.020 |
Why?
|
Administration, Inhalation | 1 | 2006 | 188 | 0.020 |
Why?
|
Mass Screening | 1 | 1990 | 617 | 0.020 |
Why?
|
Nebulizers and Vaporizers | 1 | 2006 | 55 | 0.020 |
Why?
|
Genome, Human | 1 | 2010 | 756 | 0.020 |
Why?
|
Area Under Curve | 1 | 2006 | 334 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1989 | 1961 | 0.020 |
Why?
|
Transforming Growth Factor alpha | 2 | 1995 | 50 | 0.020 |
Why?
|
DNA | 1 | 2010 | 1294 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 2004 | 228 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2006 | 377 | 0.010 |
Why?
|
Postoperative Nausea and Vomiting | 1 | 2002 | 16 | 0.010 |
Why?
|
Reference Values | 1 | 2003 | 674 | 0.010 |
Why?
|
Etomidate | 1 | 2002 | 11 | 0.010 |
Why?
|
Child | 1 | 2013 | 6926 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2004 | 230 | 0.010 |
Why?
|
Quetiapine Fumarate | 1 | 2001 | 4 | 0.010 |
Why?
|
Interleukin-10 | 1 | 2002 | 149 | 0.010 |
Why?
|
Respiratory Mechanics | 1 | 2002 | 102 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2002 | 256 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2003 | 376 | 0.010 |
Why?
|
Cells, Cultured | 2 | 1995 | 2818 | 0.010 |
Why?
|
RNA, Messenger | 2 | 1995 | 1981 | 0.010 |
Why?
|
Hemodynamics | 1 | 2002 | 710 | 0.010 |
Why?
|
Gene Expression Regulation | 2 | 1995 | 1920 | 0.010 |
Why?
|
Oligonucleotides, Antisense | 1 | 1996 | 69 | 0.010 |
Why?
|
Erythema Multiforme | 1 | 1995 | 4 | 0.010 |
Why?
|
Dermatitis Herpetiformis | 1 | 1995 | 9 | 0.010 |
Why?
|
Pemphigoid, Bullous | 1 | 1995 | 12 | 0.010 |
Why?
|
Mice, SCID | 1 | 1996 | 252 | 0.010 |
Why?
|
Epidermal Growth Factor | 1 | 1995 | 119 | 0.010 |
Why?
|
Culture Media, Conditioned | 1 | 1995 | 104 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1995 | 307 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 1995 | 135 | 0.010 |
Why?
|
Keratinocytes | 1 | 1995 | 143 | 0.010 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 1994 | 70 | 0.010 |
Why?
|
Cell Division | 1 | 1996 | 696 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1996 | 1041 | 0.010 |
Why?
|
Transfection | 1 | 1996 | 896 | 0.010 |
Why?
|
Mice, Nude | 1 | 1996 | 790 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1995 | 1014 | 0.010 |
Why?
|
Fibrinogen | 1 | 1992 | 56 | 0.010 |
Why?
|
Binding Sites | 1 | 1995 | 1098 | 0.010 |
Why?
|
Blood Coagulation | 1 | 1992 | 91 | 0.010 |
Why?
|
Capillary Permeability | 1 | 1992 | 130 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2002 | 2207 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1996 | 1056 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 1995 | 1753 | 0.010 |
Why?
|
Singapore | 1 | 1990 | 16 | 0.010 |
Why?
|
Gene Expression | 1 | 1995 | 1284 | 0.010 |
Why?
|
Base Sequence | 1 | 1994 | 2330 | 0.010 |
Why?
|
Kinetics | 1 | 1992 | 1513 | 0.010 |
Why?
|
Myocardial Revascularization | 1 | 1989 | 31 | 0.010 |
Why?
|
Pulmonary Wedge Pressure | 1 | 1989 | 108 | 0.010 |
Why?
|
Heart Valve Prosthesis | 1 | 1989 | 93 | 0.010 |
Why?
|
Heparin | 1 | 1989 | 175 | 0.010 |
Why?
|
Ultrafiltration | 1 | 1987 | 13 | 0.000 |
Why?
|
Hemofiltration | 1 | 1987 | 11 | 0.000 |
Why?
|
Radioimmunoassay | 1 | 1987 | 155 | 0.000 |
Why?
|
Diabetic Nephropathies | 1 | 1990 | 248 | 0.000 |
Why?
|
Mitral Valve | 1 | 1989 | 248 | 0.000 |
Why?
|
Solvents | 1 | 1987 | 96 | 0.000 |
Why?
|
Sex Factors | 1 | 1990 | 1054 | 0.000 |
Why?
|
Heart Rate | 1 | 1989 | 492 | 0.000 |
Why?
|
Prevalence | 1 | 1990 | 1239 | 0.000 |
Why?
|
Mice | 1 | 1996 | 11352 | 0.000 |
Why?
|